PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Authors :: K. Murai
Y. Kakinoki
Y. Ishida
T. Kitawaki
H. Shibayama
M. Hayakawa
Hiroaki Tanaka
A. Takaori
H. Nakamae
T. Hosoki
A. Kawaguchi
T. Ikezoe
J. Sakamoto
N. Takezako
T. Nishimoto
K. Ikeda
S. Kimura
J. Imagawa
N. Uoshima
M. Shindo
M. Okada
T. Sato
S. Kowata
M. Hino
R. Watanabe
T. Kobayashi
T. Kumagai
H. Ureshino
Source :: HemaSphere. 3:155-156
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Dasatinib
Oncology
medicine.medical_specialty
business.industry
Internal medicine
First line
medicine
In patient
Hematology
medicine.disease
business
medicine.drug
Chronic myelogenous leukemia

Full Text Access

Tools